Staphylococcal toxic shock syndrome in a child with interleukin-17 inhibitor treatment for psoriasis

Pediatr Dermatol. 2020 Sep;37(5):952-954. doi: 10.1111/pde.14228. Epub 2020 Jun 13.

Abstract

A 6-year-old girl presented with fever, skin rash, anuria, and conjunctivitis that rapidly progressed to toxic shock syndrome. Following hospital discharge, she developed a staphylococcal abscess on the lower extremity. She had recently received the first two doses of the interleukin-17 (IL-17) inhibitor secukinumab for resistant plaque psoriasis. IL-17 is known to be essential in host defense against Staphylococcus aureus. To our knowledge, this is the first reported case of staphylococcal toxic shock syndrome (STSS) associated with an IL-17 inhibitor.

Keywords: infection-bacterial; pediatric; psoriasis; therapy-systemic; toxic shock syndrome.

Publication types

  • Case Reports

MeSH terms

  • Child
  • Female
  • Humans
  • Interleukin-17
  • Psoriasis* / drug therapy
  • Shock, Septic* / drug therapy
  • Staphylococcal Infections* / drug therapy
  • Staphylococcus aureus

Substances

  • Interleukin-17